Abstract
Manifestations of renal disease have been reported to develop after tumor necrosis factor-α (TNF-α) inhibition, and they should be considered as a possible complication as TNF-α inhibitors become more prevalent in the treatment of autoimmune inflammatory diseases. We report a case of minimal change disease (MCD) that developed in a woman receiving the TNF-α inhibitor certolizumab and was resolved with high-dose steroids and discontinuation of TNF-α blockade.